Skip to main content

Table 2 General characteristics and levels of SphK-related sphingolipids at follow-up in the control and incident T2DM groups

From: Identification of circulating sphingosine kinase-related metabolites for prediction of type 2 diabetes

Characteristic Control
(n = 100)
Incident T2DM
(n = 100)
P value
Age, years 66.8 (60.3–74.0) 66.3 (60.3–72.2) 0.999
Body mass index, kg/m2 24.9 ± 3.1 25.7 ± 3.4 0.080
Waist circumference, cm 83.1 ± 9.2 85.5 ± 9.8 0.083
Total Cholesterol (mmol/L) 5.06 (4.41–5.64) 5.13 (4.37–5.80) 0.500
LDL (mmol/L) 2.94 ± 0.80 2.87 ± 0.89 0.523
HDL (mmol/L) 1.42 (1.12–1.69) 1.33 (1.16–1.62) 0.602
Triglycerides (mmol/L) 1.37 (1.06–1.78) 1.72 (1.27–2.30) 0.026
Fasting plasm glucose (mmol/L) 5.30 (5.10–5.60) 6.10 (5.45–7.25)  < 0.001
OGTT 2 h-plasm glucose (mmol/L) 6.10 (5.45–6.90) 12.1 (11.3–13.8)  < 0.001
Insulin (μU/mL) 6.90 (5.00–9.80) 10.8 (6.50–15.7)  < 0.001
HOMA-IR 1.62 (1.11–2.33) 2.81 (1.69–4.81)  < 0.001
Uric acid (μmol/L) 309.0 (256.0–379.5) 321.0 (265.5–377.5) 0.774
Systolic blood pressure (mmHg) 138.0 ± 20.2 142.0 ± 18.4 0.149
Diastolic blood pressure (mmHg) 77.1 ± 11.5 78.5 ± 8.6 0.335
Sphingolipids (nmol/L)    
 Sph 12.6 (7.58–19.1) 14.3 (6.8–20.7) 0.110
 S1P 740.5 (575.7–987.1) 781.1 (550.3–1072) 0.225
 S1P/Sph 60.3 (43.8–94.1) 59.9 (39.6–93.8) 0.497
 dhSph 2.88 (2.09–3.87) 3.03 (2.15–3.74) 0.570
 dhS1P 132.2 (107.7–174.2) 166.6 (103.6–203.3) 0.021
 dhS1P/dhSph 45.0 (35.6–63.9) 54.8 (44.0–66.3) 0.024
  1. Data are presented as mean ± SD, except for skewed variables, which are presented as the median with the interquartile range given in parentheses